Life Sciences & Health Care

Article

Nurturing growth

Measuring the return from pharmaceutical innovation 2021

Our latest report looks at the current state of R&D returns for 15 leading biopharma companies, the impact of the pandemic on R&D pipelines during 2021 and how this has expedited the adoption of digital solutions and impacted the IRR.

Article

Predicting the future of healthcare and life sciences in 2025

The future unmasked

What does the future hold for the life sciences and healthcare industry? Our latest predictions report looks ahead to the year 2025 to help you see what’s coming and to keep your organisation moving forward.

Article

The future of health will look very different from today

Article

Intelligent drug launch and commercial

Optimising value through AI

This is the fifth report in our Intelligent biopharma series, which explores the current and future potential of artificial intelligence (AI) across the biopharma value chain. This report focuses on how companies can use AI to improve drug launches and their commercial models.

Article

What is the future for value-based healthcare?

When talking about healthcare, the focus is often on the cost of providing treatment. Over time this has been changing: most countries with developed economies are nearing the limit of what they can afford to spend on healthcare

Perspectives

Securing trust in the global COVID-19 supply chain

From development and delivery to acceptance and administration

COVID-19 vaccines and therapeutics, and the associated medical devices and consumables, present an urgent need for a protected supply chain and a system of traceability built around globally identified products.

Perspectives

How can virtual health help expand capacity in the wake of an anticipated COVID-19 surge?

When faced with a health crisis like Covid-19, social distancing can take some of the strain off healthcare providers at the front lines.  But when that’s not enough, innovations like virtual healthcare can help increase capacity, reduce the rate of infection, and treat non-urgent cases.

Article

What COVID-19 has taught us about the adoption of AI in medicine and healthcare

Article

Intelligent drug supply chain

Creating value from AI

Protecting biopharma supply chains is a priority for companies ensuring access to lifesaving products.

Perspectives

Intelligent biopharma

Forging the links across the value chain

The biopharmaceutical sector is facing digital disruption from multiple sources, the chief among them being artificial intelligence (AI) and cloud. Deloitte predicts that in 2019/2020, all industries will accelerate their use of cloud-based AI software and services, including biopharma companies.

Perspectives

AI in Drug Discovery

Over the past 50 years, drug discovery has focused largely on high-throughput screening for known disease-associated targets. This makes drug discovery a long, expensive and largely unsuccessful process.

Perspectives

COVID-19: Shaping the future regulation of emergency medical equipment supply

The COVID-19 pandemic has disrupted everyone’s daily lives and touched every industry across the world. While many countries had influenza and other pandemic preparedness plans in place prior to COVID-19, no one was fully prepared for the speed and indiscriminate spread of the disease.

Perspectives

Who will win the race to develop an effective treatment for COVID-19

Over the past 30 years, healthcare has moved from treating infectious or communicable diseases to managing a ‘tidal wave’ of complex age and behaviour related, non-communicable, diseases.

Article

The risk of fraud in fast tracking targeted COVID-19 therapeutics

Chief Compliance Officer support

Article

Evolving the product launch paradigm in pharma
 

Successfully managing a product launch to maximise returns